What's breaking now, across thousands of outlets.
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
South Africa’s latest mortality figures put cardiovascular disease firmly in focus, with hypertension and cerebrovascular diseases among the country’s leading causes of death.
Recent PPB alerts have involved falsified cancer medicines such as Herceptin, Avastin, Ibrance,...
Back-to-back student suicides at two leading engineering institutes have once again brought the pressures faced by students into focus.
Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.
Deadly synthetic opioids disguised as legitimate painkillers are being sold online across Europe, as counterfeit medicines linked to multiple deaths in the Netherlands expose the dark side of…
Drugmakers and investors have ramped up their spending and R&D attention on autoimmune diseases in recent years, with a proliferation of bispecific T cell engagers, various approaches to CAR-T cell…
